New Positive Interim Data from Dose Escalation and Ph 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients Announced
“We are extremely pleased with the positive interim data, especially the 7.4 month mPFS in the ZFA cohort of heavily pretreated patients, which builds on the responses reported earlier and underscores the potential of zotatifin as a promising treatment option for patients with ER+ metastatic breast cancer,” said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. “The safety and tolerability data are also encouraging and have led us to reopen dose escalation of the ZFA triplet.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.